本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 石药集团新诺威制药股份有限公司（以下简称"公司"、"上市公司"、"新诺 威"）于 2023 年 9 月 11 日召开第六届董事会第四次会议，审议通过了《关于全 资子公司对外投资设立合资公司的议案》，现将具体情况公告如下： 证券代码：300765 证券简称：新诺威 公告编号：2023-063 石药集团新诺威制药股份有限公司 关于全资子公司对外投资设立合资公司的公告 一、对外投资概述 为促进公司在大健康领域功能性原料和功能食品的产业发展，充分利用全资 子公司石药集团圣雪葡萄糖有限责任公司（以下简称"石药圣雪"）的生物技术 积累和优势，加快推动石药圣雪现代生物技术在功能性原料领域的产业化应用， 石药圣雪拟与山东恒鲁生物科技有限公司（以下简称"恒鲁生物"）共同出资设 立石家庄恒鲁生物科技有限公司（暂定名，最终以注册地市场监督管理部门核准 登记的名称为准，以下简称"合资公司"），并共同签订《石药集团圣雪葡萄糖有 限责任公司和山东恒鲁生物科技有限公司有关一家拟设立于石家庄市藁城区的 公司的合资合同》（以下简称"《合资合同》" ...

本次交易有利于公司把握生物创新医药行业发展的市场机遇，进入生物创新医 药的前沿领域，进一步深化公司在大健康领域的战略布局。本次交易有利于增强公 司的竞争能力，提高公司的长期盈利能力，有利于公司长远持续发展，符合公司和 全体股东的整体利益，不会损害公司及全体股东特别是中小投资者的利益。 综上所述，我们一致同意公司本次现金增资石药集团巨石生物制药有限公司暨 关联交易事项，并同意将该议案提交至股东大会审议。 二、关于全资子公司对外投资设立合资公司的议案 石药集团新诺威制药股份有限公司独立董事 关于第六届董事会第四次会议相关事项的独立意见 我们作为石药集团新诺威制药股份有限公司（以下简称"公司"）独立董事审 议了公司第六届董事会第四次会议相关议案。根据《公司章程》《独立董事工作 细则》等相关规定，并参照《关于在上市公司建立独立董事制度的指导意见》《深 圳证券交易所创业板股票上市规则》《上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等法律、法规、规范性文件的规定，本着对公司、全体股东负责的 态度，对公司下列事项进行了认真了解和查验，现就公司第六届董事会第四次会议的 相关事项发表独立意见如下： 一、关于公司 ...

石药集团新诺威制药股份有限公司 章 程 2023 年 9 月 第三条 公司由石药控股集团有限公司、石家庄制药集团进出口贸易有限 公司以发起方式设立，在石家庄市工商行政管理局注册登记，取得营业执照，统 一社会信用代码为 91130100787019708G。 1 | | | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和经营范围 4 | | 第三章 | 股份 4 | | 第一节 | 股份发行 4 | | 第二节 | 股份增减和回购 5 | | 第三节 | 股份转让 7 | | 第四章 | 股东和股东大会 8 | | 第一节 | 股东 8 | | 第二节 | 股东大会的一般规定 10 | | 第三节 | 股东大会的召集 13 | | 第四节 | 股东大会提案与通知 15 | | 第五节 | 股东大会的召开 16 | | 第六节 | 股东大会的表决和决议 19 | | 第五章 | 董事会 23 | | 第一节 | 董事 23 | | 第二节 | 独立董事 27 | | 第三节 | 董事会 30 | | 第四节 | 董事会专门委员会 34 | | 第六章 | 总经理及其他高级管理 ...

2022 年 10 月 12 日，公司收到中国证监会于 2022 年 10 月 8 日核发的《关 于同意石药集团新诺威制药股份有限公司向石药集团恩必普药业有限公司发行 股份购买资产并募集配套资金注册的批复》（证监许可[2022]2365 号），同意公司 发行股份募集配套资金不超过 5 亿元的注册申请。公司向特定对象发行股份募集 配套资金的股份数量为 31,486,146 股，募集资金总额为 499,999,998.48 元。募集 配套资金新增股份于 2023 年 3 月 10 日在深圳证券交易所上市，股份限售期为 6 个月。本次发行后公司总股本增加至 650,412,308 股。 安信证券股份有限公司 关于石药集团新诺威制药股份有限公司 发行股份购买资产并募集配套资金暨关联交易之 部分限售股份上市流通的核查意见 安信证券股份有限公司（以下简称"安信证券"或"独立财务顾问"）作为石药 集团新诺威制药股份有限公司（以下简称"公司"或"新诺威"）发行股份购买资产 并募集配套资金暨关联交易（以下简称"本次交易"）的独立财务顾问，根据《上 市公司重大资产重组管理办法》《深圳证券交易所创业板股票上市规则》《深圳证 券交易 ...

证券代码：300765 证券简称：新诺威 公告编号：2023-059 特别提示： 1、本次解除限售的股份为石药集团新诺威制药股份有限公司（以下简称"公 司"或"新诺威"）发行股份购买资产并募集配套资金暨关联交易之募集配套资 金的限售股份。 2、本次解除限售股份的上市流通日期为 2023 年 9 月 11 日； 3、本次解除限售股份数量为 56,675,062 股，占公司总股本的 4.8410%，其 中，本次解除股份限售涉及公司可上市流通的股份数量为 56,675,062 股，占公司 总股本的 4.8410%； 4、本次申请解除股份限售的股东数为 16 名，对应 53 个证券账户。 一、本次解除限售的股份取得和股本变化情况 （一）本次解除限售的股份取得情况 石药集团新诺威制药股份有限公司 关于发行股份购买资产并募集配套资金暨关联交易之 部分限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2022 年 10 月 12 日，公司收到中国证监会于 2022 年 10 月 8 日核发的《关 于同意石药集团新诺威制药股份有限公司向石药集团恩必 ...

证券代码：300765 证券简称：新诺威 公告编号：2023-058 石药集团新诺威制药股份有限公司 关于筹划对石药集团巨石生物制药有限公司增资暨 关联交易的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、石药集团新诺威制药股份有限公司（以下简称"公司"、"上市公司"） 正在筹划对石药集团巨石生物制药有限公司（以下简称"巨石生物"或"标的公 司"）实施现金增资（以下简称"本次增资"），取得标的公司 51%以上的股权， 实现对标的公司的控股。相关各方已于 2023 年 8 月 30 日签署了《关于石药集团 巨石生物制药有限公司增资之意向协议》（以下简称"《增资意向协议》"）。 2、本次增资构成关联交易。经初步研究和测算，本次交易预计不构成重大 资产重组。 3、本次签署的《增资意向协议》仅为各方合作意愿的意向性约定，具体的 交易方案及相关交易条款以各方最终签署的正式协议为准。 4、本次增资尚处于筹划阶段，具体交易方案仍处于论证协商中，并需按照 相关法律、法规及公司章程的规定履行必要的决策和审批程序，存在未能通过该 等决策、审批程序的风险 ...

证券代码：300765 证券简称：新诺威 公告编号：2023-057 石药集团新诺威制药股份有限公司 关于 2023 年半年度募集资金存放与使用情况的专项报告 及 2023 年半年度报告的更正公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1 | 募集资金 | 序号 | 开户银行 | 开户公司 | 银行账户 | 账户余额 | 存放方式 | | --- | --- | --- | --- | --- | --- | --- | | | 6 | 上海浦东发展银 行股份有限公司 石家庄分行 | 石药圣雪 | 450100788011000 03503 | 7,882,301 | 活期存储 | | | | 合计 | | | 308,649,526.01 | | | | | 总计 | | | 693,381,790.66 | - | 更正后： | 募集资金 | 序号 | 开户银行 | 开户公司 | 银行账户 | 账户余额 | 存放方式 | | --- | --- | --- | --- | --- | --- | --- | | 首次公开发 行募集资金 | 1 | ...

（1）首次公开发行募集资金情况 石药集团新诺威制药股份有限公司经中国证券监督管理委员会《关于核准石 药集团新诺威制药股份有限公司首次公开发行股票的批复》（证监许可[2019]288 号）核准，并经深圳证券交易所《关于石药集团新诺威制药股份有限公司人民币 普通股股票在创业板上市的通知》（深证上[2019]133 号）同意，公司公开发行的 人民币普通股股票已于 2019 年 3 月 22 日在深圳证券交易所创业板上市交易。公 司首次公开发行人民币普通股（A 股）50,000,000 股，发行价格 24.47 元/股，募 集资金总额 1,223,500,000.00 元，保荐机构（主承销商）安信证券有限公司扣除 承销及保荐费用 71,271,300.00 元后，于 2019 年 3 月 19 日将 1,152,228,700.00 元 划至公司募集资金专户。再行扣除审计验资费用、律师费用、信息披露费用及发 行手续费合计 9,819,490.53 元后，募集资金净额为 1,142,409,209.47 元。 石药集团新诺威制药股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 根据《深圳证券交易所上市公 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥1.31 billion, representing a 5.47% increase compared to ¥1.04 billion in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥400.62 million, a 20.72% increase from ¥302.37 million in the previous year[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥394.04 million, reflecting a 30.59% increase compared to ¥301.73 million in the same period last year[21]. - The net cash flow from operating activities was approximately ¥346.37 million, up 32.99% from ¥211.31 million in the previous year[21]. - Total assets at the end of the reporting period were approximately ¥5.28 billion, a 15.11% increase from ¥4.58 billion at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥4.73 billion, representing a 20.15% increase from ¥3.94 billion at the end of the previous year[21]. - The basic earnings per share for the first half of 2023 were ¥0.3507, a 3.85% increase from ¥0.3377 in the previous year[21]. - The diluted earnings per share were also ¥0.3507, reflecting the same increase of 3.85% compared to the previous year[21]. - The weighted average return on equity was 9.21%, a slight decrease of 0.39% from 9.60% in the previous year[21]. - The company reported a gross margin of 45%, reflecting improved operational efficiency compared to the previous year[40]. Market Expansion and Product Development - The company is focusing on high-end market development, increasing the sales proportion of high-end products[34]. - The company is actively exploring new retail channels and e-commerce platforms to diversify its sales strategy[35]. - The company has launched over 20 new functional health products, achieving a production capacity of 130 million units during the reporting period[36]. - The company is focusing on expanding its product line in areas such as eye care, liver protection, and sports nutrition through continuous market research and innovation[36]. - The company is actively pursuing market expansion and innovation in functional products to meet consumer and industry demands[36]. - The company is collaborating with various subsidiaries to optimize the production and approval process of health food products[39]. - The company plans to enhance its supply chain logistics, aiming to reduce delivery times by 15% in the next quarter[40]. - The company is investing in R&D for new health supplements, with a budget allocation of 200 million CNY for the next fiscal year[40]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting companies with complementary health products[40]. - The company has established overseas sales offices to enhance market penetration in North America, South America, Europe, and South Asia[34]. Sustainability and Compliance - The company has achieved a silver rating in the Ecovadis assessment, reflecting its commitment to sustainable practices[34]. - The company is committed to adhering to the disclosure requirements set by the Shenzhen Stock Exchange for food and beverage manufacturing[36]. - The company emphasizes strict budget management and cost control in the implementation of fundraising projects to enhance efficiency[78]. - The company has established a comprehensive food safety quality control system and has never experienced a major food safety incident since its establishment[87]. - The company strictly adheres to various environmental protection laws and regulations, including the Environmental Protection Law of the People's Republic of China[96]. - The company has implemented a comprehensive energy management system to reduce carbon emissions and improve energy efficiency, aligning with national energy-saving regulations[106]. Shareholder and Capital Management - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The total number of shares increased to 1,170,742,154 after a capital reserve conversion, with a distribution of 8 shares for every 10 held during the 2022 profit distribution[133]. - The company issued 31,486,146 new ordinary shares at a price of ¥15.88 per share, raising a total of ¥499,999,998.48, with a net amount of ¥488,195,415.53 after deducting fees[72]. - The largest shareholder, Shijiazhuang Pharmaceutical Group, holds 73.35% of the shares, amounting to 381,649,082 shares[142]. - The company has not reported any major contracts or guarantees during the reporting period[128][127]. Operational Efficiency and Cost Management - The company reported a decrease in direct material costs by 10.57% year-on-year, with direct material costs amounting to CNY 351.85 million, which constituted 50.99% of the total operating costs[55]. - The sales expenses decreased by 11.34% to CNY 108,238,686.40, down from CNY 122,079,824.10 in the previous year, indicating improved cost management[62]. - The company's management expenses increased by 44.95% to CNY 39,630,755.86, primarily due to higher personnel costs and depreciation[62]. - The company has implemented measures to refine responsibilities and improve operational procedures, contributing to overall efficiency and effectiveness[36]. Risks and Challenges - The company faces market competition risks due to high quality and brand requirements from downstream customers in the functional raw materials industry[85]. - The company is exposed to raw material price fluctuation risks, with a high proportion of direct materials in operating costs[86]. - The company emphasizes continuous R&D investment and market demand orientation to mitigate new product development risks[87]. - The company will closely monitor exchange rate fluctuations as its export business is a significant source of revenue and profit[86].

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥1.31 billion, representing a 5.47% increase compared to the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥400.62 million, reflecting a 20.72% increase year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥394.04 million, which is a 30.59% increase compared to the previous year[21]. - The net cash flow from operating activities for the first half of 2023 was approximately ¥346.37 million, up 32.99% from the same period last year[21]. - Total assets as of June 30, 2023, were approximately ¥5.28 billion, marking a 15.11% increase from the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥4.73 billion, which is a 20.15% increase year-on-year[21]. - The basic earnings per share for the first half of 2023 were ¥0.3507, a 3.85% increase compared to the same period last year[21]. - The company reported a total comprehensive income of CNY 402.49 million for the first half of 2023, compared to CNY 332.50 million in the same period of 2022, marking an increase of 20.9%[167]. - The company reported a significant increase in user data, with a total of 1.5 million active users, reflecting a growth rate of 30% compared to the previous year[178]. Market Expansion and Product Development - The company is focusing on high-end market development, increasing the sales proportion of high-end products[34]. - The company is actively exploring new retail channels and e-commerce platforms to diversify its sales strategy[35]. - The company has launched over 20 new functional health products, achieving a production capacity of 130 million units during the reporting period[36]. - The company has obtained 18 new health food product approvals during the reporting period, expanding its product line and enhancing market competitiveness[35]. - The company is expanding its market presence in Southeast Asia, targeting a 20% market share in the region by 2025[175]. - New product launches are expected to contribute an additional 200 million CNY in revenue by the end of 2023[176]. - The company has initiated two strategic acquisitions in the healthcare sector, expected to enhance its product portfolio and increase revenue by 10% in the next fiscal year[179]. - The company plans to continue expanding its market presence and invest in new product development to drive future growth[183]. Research and Development - The company is investing in research and development for new health supplements, with a budget increase of 30% for R&D activities in 2023[40]. - Research and development expenses increased to CNY 22,313,725.52, a rise of 61.5% compared to CNY 13,813,998.98 in the previous year[163]. - The company plans to increase its R&D investment by 15% in the next fiscal year to enhance product development and innovation capabilities[175]. - The company has implemented new equipment and processes to improve production efficiency and product quality[34]. Financial Management and Investments - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[4]. - The total amount of funds raised during the reporting period was ¥163,060.46 million, with ¥20,421.5 million invested from the raised funds[70]. - The company's financial expenses decreased by 32.82% to -¥41,017,226.49, mainly due to an increase in interest income[60]. - The total cash inflow from financing activities was CNY 488,799,998.48, with cash outflows for dividend payments amounting to CNY 97,561,846.20[172]. Risk Management - The company has outlined potential risk factors and countermeasures in its management discussion and analysis section[3]. - The company faces market competition risks, particularly in the functional raw materials industry, which may lead to increased competition and potential declines in gross margins[83]. - The company has implemented measures to optimize supply chain management and reduce costs to mitigate risks associated with raw material price fluctuations[84]. - The company is exposed to exchange rate risks due to its reliance on export business, which is a significant source of revenue and profit[84]. Environmental and Social Responsibility - The company has established a comprehensive food safety quality control system and has not experienced any major food safety incidents since its inception[85]. - The company emphasizes continuous R&D investment and market demand orientation to mitigate risks associated with new product development[85]. - The company strictly adheres to various environmental protection laws and regulations, including the Environmental Protection Law of the People's Republic of China and the Air Pollution Prevention and Control Law[94]. - The company actively engages in social responsibility, ensuring transparent communication with investors and adhering to a stable dividend policy[105]. Corporate Governance - The company experienced changes in its board of directors, with several members completing their terms on April 7, 2023[89]. - The company appointed a new board secretary and CFO, Dai Long, on April 7, 2023[90]. - The first extraordinary general meeting of 2023 had an investor participation rate of 80.41%[88]. - The company did not implement any stock incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period[92].